Novartis shares tumble after second late-stage drug setback
Novartis shares fell after the company reported a second late-stage clinical setback. Its global Phase III HARBOR study in myotonic dystrophy type 1 (DM1) did not demonstrate a statistic.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.